Table 3.

PROs by Clinical Groups Defined by sPCDAI Change

	Active - Improved	Active - Not Improved	Inactive - Inactive
n	39	32	60
IBD Symptoms
Baseline mean (SD)	57 (±7)	56 (±5)	53 (±7)
First follow-up mean (SD)	51 (±6)	55 (±6)	50 (±6)
Effect size (Cohen’s d)	−0.85	−0.10	−0.55
p-value	<0.001	0.59	<0.001
Pain Interference
Baseline mean (SD)	53 (±14)	56 (±11)	41 (±13)
First follow-up mean (SD)	40 (±12)	49 (±11)	36 (±11)
Effect size (Cohen’s d)	−0.93	−0.61	−0.37
p-value	<0.001	<0.01	<0.01
Fatigue
Baseline mean (SD)	50 (±17)	55 (±13)	44 (±14)
First follow-up mean (SD)	41 (±16)	50 (±15)	38 (±13)
Effect size (Cohen’s d)	−0.58	−0.51	−0.35
p-value	<0.001	<0.01	<0.01
Positive Affect
Baseline mean (SD)	47 (±10)	45 (±7)	50 (±9)
First follow-up mean (SD)	49 (±10)	45 (±8)	52 (±8)
Effect size (Cohen’s d)	0.27	0.00	0.18
p-value	0.10	0.98	0.17